SEC Form 3 · accession 0001140361-18-009548
Arbutus Biopharma Corp · ABUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Koert VandenEnden
Officer — Interim CFO
Period of report
Feb 16, 2018
Accepted (ET)
Feb 22, 2018 · 1:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001447028
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares | holding | — | — | — | 2,750 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F1 | $3.05 | holding | — | — | — | Dec 7, 2016 | Oct 3, 2026 | Common Shares | 35,000 | — | D |
| Stock Options (Right to Buy)F2 | $3.15 | holding | — | — | — | Mar 24, 2017 | Mar 24, 2027 | Common Shares | 15,000 | — | D |
Explanation of responses
- F1Grant date is reflected above. The options vest as follows: 1/3 on 10/3/2017; 1/3 on 10/3/2018 and 1/3 on 10/3/2019.
- F2Grant date is reflected above. The options vest as follows: 1/3 on 3/24/2018; 1/3 on 3/24/2019; and 1/3 on 3/24/2020.